Celecoxib + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Colorectal Adenoma

Conditions

Colorectal Adenoma, Colorectal Carcinoma

Trial Timeline

Dec 1, 2001 → Jun 1, 2008

NCT ID

NCT00582660

About Celecoxib + Placebo

Celecoxib + Placebo is a phase 2 stage product being developed by Pfizer for Colorectal Adenoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00582660. Target conditions include Colorectal Adenoma, Colorectal Carcinoma.

What happened to similar drugs?

15 of 20 similar drugs in Colorectal Adenoma were approved

Approved (15) Terminated (3) Active (4)

✅Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved

✅Cetuximab (EGFR inhibitor) + Bevacizumab + Irinotecan (CPT-11) + Oxaliplatin + Leucovorin and 5-FU + CapecitabineMerckApproved

✅5-FU based doublet chemotherapy + bevacizumabRocheApproved

✅capecitabine [Xeloda]RocheApproved

✅5-Fluorouracil + Bevacizumab + Irinotecan + OxaliplatinRocheApproved

✅Oxaliplatin + Capecitabine + Bevacizumab + Leucovorin + 5-Fluouracil + IrinotecanRocheApproved

✅CapecitabineRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01186887	Pre-clinical	Completed	Feb 1, 2009	Apr 1, 2013	Pain
NCT00583453	Phase 2	Completed	Oct 1, 2007	May 1, 2016	Tonsillitis
NCT00359151	Approved	Terminated	Nov 1, 2006	Jul 1, 2007	Osteoarthritis
NCT00585312	Phase 3	Terminated	Sep 1, 2006	Oct 1, 2013	Adenomatous Polyposis Coli
NCT00300729	Phase 3	UNKNOWN	May 1, 2006	Sep 1, 2010	Non-Small Cell Lung Cancer
NCT00640627	Approved	Completed	Dec 1, 2003	Sep 1, 2004	Osteoarthritis, Knee
NCT00698204	Phase 2	Completed	Jul 1, 2003	Dec 1, 2013	Oral Mucositis
NCT00639483	Phase 2	Completed	Mar 1, 2003	Jan 1, 2004	Schizophrenia
NCT00471341	Approved	Completed	Jul 1, 2002	Dec 1, 2004	Hypertension and Coronary Artery Disease
NCT00582660	Phase 2	Completed	Dec 1, 2001	Jun 1, 2008	Colorectal Adenoma
NCT02840162	Phase 2	Terminated	May 1, 2001	May 1, 2011	Adenocarcinoma of the Prostate

Competing Products

20 competing products in Colorectal Adenoma

See all competitors

Product	Company	Stage	Hype Score
Cetuximab + Oxaliplatin + Capecitabine	Eli Lilly	Phase 2	35
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FU	Eli Lilly	Phase 2	35
ZN-c3 + Encorafenib + Cetuximab	Zentalis Pharmaceuticals	Phase 1	11
ALIMTA + Oxaliplatin	Eli Lilly	Phase 2	35
eFT508 + Avelumab	eFFECTOR Therapeutics	Phase 2	25
Bevacizumab + Oxaliplatin + Capecitabine	Chugai Pharmaceutical	Phase 1/2	32
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + Capecitabine	Chugai Pharmaceutical	Phase 2	31
FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOX	Chugai Pharmaceutical	Phase 2/3	38
Gemcitabine and UFTE chemotherapy	Yuhan	Phase 2	35
CPT-11 and TS-1 + CPT-11, 5-FU and l-LV	Daiichi Sankyo	Phase 2/3	38
CPT-11 based regimens	Daiichi Sankyo	Pre-clinical	26
CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)	Daiichi Sankyo	Phase 2	35
Tivantinib + Placebo + Cetuximab + Irinotecan	Daiichi Sankyo	Phase 1/2	32
DS-8201a 5.4 mg/kg Q3W + DS-8201a 6.4 mg/kg Q3W	Daiichi Sankyo	Phase 2	35
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
CS-1008 + irinotecan	Daiichi Sankyo	Phase 2	27
CS-7017 + Placebo	Daiichi Sankyo	Phase 2	27
Patritumab Deruxtecan	Daiichi Sankyo	Phase 2	27
CS-1008 + FOLFIRI	Daiichi Sankyo	Phase 1	29
DS-8273a + nivolumab	Daiichi Sankyo	Phase 1	21